Cargando…
Therapeutic Targeting of Pancreatic Cancer via EphA2 Dimeric Agonistic Agents
Recently, we reported on potent EphA2 targeting compounds and demonstrated that dimeric versions of such agents can exhibit remarkably increased agonistic activity in cellular assays compared to the monomers. Here we further characterize the activity of dimeric compounds at the structural, biochemic...
Autores principales: | Salem, Ahmed F., Gambini, Luca, Udompholkul, Parima, Baggio, Carlo, Pellecchia, Maurizio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281375/ https://www.ncbi.nlm.nih.gov/pubmed/32397624 http://dx.doi.org/10.3390/ph13050090 |
Ejemplares similares
-
Targefrin:
A Potent Agent Targeting the Ligand Binding
Domain of EphA2
por: Baggio, Carlo, et al.
Publicado: (2022) -
Effective Tumor Targeting by EphA2-Agonist-Biotin-Streptavidin Conjugates
por: Udompholkul, Parima, et al.
Publicado: (2021) -
Reduction of Circulating
Cancer Cells and Metastases
in Breast-Cancer Models by a Potent EphA2-Agonistic Peptide–Drug
Conjugate
por: Salem, Ahmed F., et al.
Publicado: (2018) -
Mixture-Based Screening
of Focused Combinatorial Libraries
by NMR: Application to the Antiapoptotic Protein hMcl-1
por: Alboreggia, Giulia, et al.
Publicado: (2023) -
Prostate Cancer Metastases Are Strongly Inhibited by Agonistic Epha2 Ligands in an Orthotopic Mouse Model
por: Salem, Ahmed F., et al.
Publicado: (2020)